Your browser doesn't support javascript.
loading
Changes in atherosclerotic cardiovascular disease risk over time among people living with HIV.
Chen, Weisi; Petoumenos, Kathy; Somia, Agus; Edmiston, Natalie; Chaiwarith, Romanee; Woolley, Ian; Ross, Jeremy; Pujari, Sanjay; Boettiger, David C.
Afiliação
  • Chen W; Kirby Institute, UNSW Sydney, Sydney, Australia.
  • Petoumenos K; Kirby Institute, UNSW Sydney, Sydney, Australia.
  • Somia A; Department of Tropical and Infectious Diseases, Udayana University, Denpasar, Indonesia.
  • Edmiston N; School of Medicine, Rural Research, Western Sydney University, Sydney, Australia.
  • Chaiwarith R; Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Woolley I; Monash Infectious Diseases, Monash Health and Monash University, Melbourne, Australia.
  • Ross J; TREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.
  • Pujari S; Institute of Infectious Diseases, Pune, India.
  • Boettiger DC; Kirby Institute, UNSW Sydney, Sydney, Australia.
J Antimicrob Chemother ; 79(4): 897-902, 2024 04 02.
Article em En | MEDLINE | ID: mdl-38416697
ABSTRACT

OBJECTIVE:

To describe changes in atherosclerotic cardiovascular disease (ASCVD) risk over time among people living with HIV (PLHIV).

METHODS:

We used data from the TREAT Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD). Five-year ASCVD risk was calculated using the DAD equation. Individuals were eligible for inclusion if they were aged ≥18 years, had started ART, had no previous history of ASCVD and had complete ASCVD risk factor data available within the first 5 years of ART initiation.

RESULTS:

A total of 3368 adults contributed data, 3221 were from TAHOD and 147 were from AHOD. The median age at ART initiation was 36 [IQR 31-43] years for TAHOD participants, and 42 [IQR 35-50] years for AHOD participants. Most TAHOD (70.4%) and AHOD (91.8%) participants were male. Overall, ASCVD risk increased from 0.84% (95% CI 0.81%-0.87%) at ART initiation to 1.34% (95% CI 1.29%-1.39%) after 5 years on ART. After adjusting for traditional and HIV-associated ASCVD risk factors, ASCVD risk increased at a similar rate among sub-populations defined by HIV exposure (heterosexuals, men who have sex with men, people who inject drugs), race/ethnicity (Caucasian and Asian) and nadir CD4 at ART initiation (<200 and ≥200 cells/mm3).

CONCLUSIONS:

These findings emphasize the growing burden of ASCVD risk among PLHIV and the need to develop interventions that are effective across a broad range of HIV sub-populations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Infecções por HIV / Fármacos Anti-HIV / Aterosclerose / Minorias Sexuais e de Gênero Limite: Adolescent / Adult / Female / Humans / Male País como assunto: Oceania Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Infecções por HIV / Fármacos Anti-HIV / Aterosclerose / Minorias Sexuais e de Gênero Limite: Adolescent / Adult / Female / Humans / Male País como assunto: Oceania Idioma: En Ano de publicação: 2024 Tipo de documento: Article